Merck's rotavirus vaccine RotaTeq has faced close scrutiny since winning FDA approval in 2006, with authorities monitoring whether it shares side effects with a similar Wyeth product that was pulled from the market. Now a FDA-funded study has shown RotaTeq is linked to the side effect, but the benefits outweigh the risks.
The number of rotavirus-related hospitalizations in kids under 5 fell by 80% after the shots went into routine use, and the hospitalizations in kids 5-14 years dropped by 70%.
A U.S. Centers for Disease Control and Prevention team has found a significant decrease in the number of rotavirus-related hospitalizations with routine use of GlaxoSmithKline ($GSK) and Merck's ($MRK) rotavirus vaccines in older age groups.
The data dampen concerns about Rotarix' efficacy raised in an earlier clinical trial, and shows both vaccines to be effective.
Sales of GlaxoSmithKline's rotavirus vaccine Rotarix and Merck's shingles vaccine Zostavax will be buoyed by their inclusion on the U.K. national immunization schedule.
British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
Rwanda's government has launched a national rotavirus vaccination program using Merck's RotaTeq oral rotavirus vaccine. The program will include all infants in the country, meaning that over 100,000 children will get the vaccine before the end of 2012.
The deal cuts the price for the vaccines 67 percent and means vaccines for 70 million children in the world's 40 poorest countries by 2016.